欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (3): 305-311.

• 药物治疗学 • 上一篇    下一篇

脐带间充质干细胞治疗严重膝骨关节炎的对照研究

杨孝兵1,蒋 峰1,张 帆1,施星芬1,刘丽敏1,徐志国2   

  1. 1 浙江湖州市第三人民医院风湿免疫科,2 协和华东干细胞基因工程有限公司,湖州 313000,浙江
  • 收稿日期:2015-11-26 修回日期:2017-02-13 出版日期:2017-03-26 发布日期:2017-03-29
  • 作者简介:杨孝兵,男,硕士,主治医师,研究方向: 风湿免疫病干细胞治疗。 Tel:15088354361 E-mail:yxb0516@126.com
  • 基金资助:

    浙江省湖州市生物医药重大专项计划(2011ZD2007)

Therapeutic effect of human umbilical cord-derived mesenchymal stem cells for severe knee osteoarthritis

YANG Xiaobing 1, JIANG Feng 1, ZHANG Fan 1, SHI Xingfen 1, LIU Limin 1, XU Zhiguo 2   

  1. 1 Department of Rheumatology and Immunology, Huzhou Third Municipal Hospital, Huzhou 313000, Zhejiang, China; 2 Eastern Union Stem Cell and Gene Engineering Co., Ltd. Huzhou 313000, Zhejiang, China
  • Received:2015-11-26 Revised:2017-02-13 Online:2017-03-26 Published:2017-03-29

摘要:

目的:对照透明质酸钠(sodium hyaluronate or hyaluronic acid,HA)与人源脐带间充质干细胞(human umbilical cord derived mesenchymal stem cells,hUC-MSCs)膝关节腔两种注射方法治疗中重度膝骨关节炎(osteoarthritis,OA),观察关节疼痛、功能的疗效、放射学变化以及安全性。方法:采用随机半盲平行对照的研究方法,将44例中重度膝骨关节炎的患者分为3组:A组16例,5次透明质酸钠注射组;B组15例,2次hUC-MSCs注射组;C组13例,4次hUC-MSCs注射组。观察指标:静止VAP评分,美国膝关节协会 (AKS)的膝骨关节炎关节性和功能性评分,Kellgren-Lawrence(K-L)放射学评估。随访期12个月,治疗前和治疗后3、6、12个月进行随访记录临床体检、观察指标结果及安全性评估;治疗前和治疗后6、12个月进行实验室检查和膝关节X片检查。结果: 3组治疗前比较,静止VAP评分、AKS关节性评分、AKS功能评分、K-L放射学评估均无统计学差异(P>0.05)。治疗后3、6、12个月时,3组间静止VAP评分、AKS关节性评分、AKS功能评分比较均有统计学差异(P<0.05,P<0.01);K-L放射学评估各时段各组间比较差异均无统计学意义(P>0.05)。结论:hUC-MSCs移植治疗严重OA较透明质酸钠能更快速、更显著、更持久地减轻关节疼痛、改善关节功能,4次注射疗效优于2次注射。

关键词: 骨关节炎, 脐带间充质干细胞, 透明质酸钠

Abstract:

AIM: To explore the therapeutic effect of two methods of knee joint cavity injection in treating sodium hyaluronate and human umbilical cord-derived mesenchymal stem cells for severe knee osteoarthritis by evaluating pain degree, clinical effect, radiological change, and safety.  METHODS: In this semi-blind parallelling study, 44 severe knee osteoarthritis patients were randomly divided into 3 groups. 16 patients in group A were injected with sodium hyaluronate 5 times individually. 15 patients in group B were injected with human umbilical cord-derived mesenchymal stem cells twice. 13 patients in group C were injected with human umbilical cord-derived mesenchymal stem cells 4 times. VAP scores, American Knee Society Knee scores, and Kellgren-Lawrence radiographic evaluation were evaluated. Follow-up were conducted 3, 6 and 12 months after treatment for recording clinical examination, evaluating observed indicators and safety assessment. Laboratory tests and X-ray examination of the knee were checked 6 and 12 months after treatment independently. RESULTS: VAP scores: significant difference were found in three groups before and 3, 6, 12 months after treatment; results showed that there were significant difference in group A 12 months after treatment comparing with group B and group C. AKS scores: significant difference were found in group B and group C before and 3, 6, 12 months after treatment; AKS Function: significant difference were found in group B and group C before and 3, 6, 12 months after treatment; Kellgren-Lawrence radiographic evaluation: no significant difference were found during the study. CONCLUSION: Comparing with sodium hyaluronate injection, the therapeutic effect of human umbilical cord-derived mesenchymal stem cells for severe knee osteoarthritis was more effective in relieving pain and improving joint function. Four times injections are better than two times injection.

Key words: osteoarthritis, human umbilical cord derived mesenchymal stem cells, sodium hyaluronate

中图分类号: